Heron Therapeutics, Inc. Provides Update On Sustol Resubmission

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced an approximate one-quarter delay to the Company’s timeline for the resubmission of the new drug application (NDA) for Sustol® to the U.S. Food and Drug Administration (FDA), the Company’s product candidate for chemotherapy-induced nausea and vomiting (CINV).

Help employers find you! Check out all the jobs and post your resume.

Back to news